Collagen is the most abundant protein in the body, and is the main component in human connective tissues. Current commercial and experimental use of collagen soft tissue fillers include applications in urinary incontinence (urology), coronary implants (cardiovascular), musculoskeletal regeneration (orthopaedic) and skin correction (cosmetic procedures).
EternoGen's innovative collagen scaffold enhanced by nanotechnology
provides a superior collagen soft tissue filler to expand product
capabilities in each of the aforementioned industries.
main drawback of current collagen soft tissue fillers on the market is
that they are decomposed by enzymes such that the implants have a
limited effective duration. EternoGen
is actively pursuing commercialization of a novel collagen matrix
having the following bio-histochemical characteristics: reduced native
collagen enzymatic degradation, increased fibroblast cellular
interaction, and improved tissue in-growth.
This matrix is generated through EternoGen's patent pending NanoScaffolding technology which enables the precise conjugation of Gold Nanoparticles to collagen. The nano-engineered properties of the matrix are further differentiated from competitors through
its ability to act as an antioxidant, anti-inflammatory and
antimicrobial agent. Furthermore, EternoGen achieves all these improvements with less than 1 percent change in the natural formulation of collagen.